SCHEMBL4348680

SCHEMBL4348680

O=Cc1ccc(OC2CCCC2)c(Oc2ccc([N+](=O)[O-])cc2Br)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.46
CYP19A1 P11511 5/20 0.46
MAPT P10636 7/20 0.43
ALDH1A1 P00352 5/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
PTGS2 P35354 2/20 0.43
PTGES O14684 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
PTGS1 P23219 1/20 0.43
CYP2C19 P33261 1/20 0.43
LMNA P02545 5/20 0.41
POLB P06746 4/20 0.37
NPSR1 Q6W5P4 3/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8270211 0.87 TTR (0.46) TTRCYP19A1MAPTALDH1A1SMN1; SMN2
SCHEMBL20384249 0.82 CYP19A1 (0.56) CYP19A1MAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL1302147 0.81 TTR (0.49) TTRCYP19A1MAPTALDH1A1SMN1; SMN2
SCHEMBL4352112 0.81 ALDH1A1 (0.43) TTRCYP19A1MAPTALDH1A1SMN1; SMN2
SCHEMBL7895387 0.79 TTR (0.62) TTRCYP19A1MAPTALDH1A1SMN1; SMN2
SCHEMBL2791777 0.78 POLB (0.39) ALDH1A1TSHRPOLBPDE4BPDE3A
SCHEMBL2353542 0.76 POLB (0.47) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL25370111 0.76 POLB (0.46) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL2560121 0.76 TTR (0.40) TTRCYP19A1MAPTALDH1A1SMN1; SMN2
SCHEMBL8845986 0.76 PDE4B (0.49) ALDH1A1TSHRPOLBPDE4BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090281146-A1 PROCESS FOR THE PREPARATION OF N-(3,5-DICHLOROPYRID-4-YL)-4-DIFLUOROMETHOXY-8-METHANESULFONAMIDO-DIBENZO[B,D]FURAN-1-CARBOXAMIDE GLENMARK PHARMACEUTICALS, S.A. (CH) 2009-11-12 US claimed
US-7563900-B2 Process for the preparation N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methane sulfonamido-dibenzo[b,d]furan-1-carboxamide GLENMARK PHARMACEUTICALS S.A. (CH) 2009-07-21 US claimed
EP-1799632-A2 PROCESS FOR THE PREPARATION OF N-(3,5-DICHLOROPYRID-4-YL)-4-DIFLUOROMETHOXY-8-METHANESULFONAMIDO-DIBENZO[B,D]FURAN-1-CARBOXAMIDE Glenmark Pharmaceuticals S.A. (CH) 2007-06-27 EP claimed
WO-2006040652-A2 PROCESS FOR THE PREPARATION OF N-(3,5-DICHLOROPYRID-4-YL)-4DIFLUOROMETHOXY-8-METHANESULFONAMIDO-DIBENZO[B,D]FURAN-1-CARBOXAMIDE GLENMARK PHARMACEUTICALS S.A. (US) 2006-04-20 WO claimed
WO-2009147476-A1 NOVEL PDE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION MATRIX LABORATORIES LTD. (IN) 2009-12-10 WO disclosed
US-20090281146-A1 PROCESS FOR THE PREPARATION OF N-(3,5-DICHLOROPYRID-4-YL)-4-DIFLUOROMETHOXY-8-METHANESULFONAMIDO-DIBENZO[B,D]FURAN-1-CARBOXAMIDE GLENMARK PHARMACEUTICALS, S.A. (CH) 2009-11-12 US disclosed
US-20090281146-A1 PROCESS FOR THE PREPARATION OF N-(3,5-DICHLOROPYRID-4-YL)-4-DIFLUOROMETHOXY-8-METHANESULFONAMIDO-DIBENZO[B,D]FURAN-1-CARBOXAMIDE GLENMARK PHARMACEUTICALS, S.A. (CH) 2009-11-12 US disclosed
US-20090281146-A1 PROCESS FOR THE PREPARATION OF N-(3,5-DICHLOROPYRID-4-YL)-4-DIFLUOROMETHOXY-8-METHANESULFONAMIDO-DIBENZO[B,D]FURAN-1-CARBOXAMIDE GLENMARK PHARMACEUTICALS, S.A. (CH) 2009-11-12 US disclosed
US-7563900-B2 Process for the preparation N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methane sulfonamido-dibenzo[b,d]furan-1-carboxamide GLENMARK PHARMACEUTICALS S.A. (CH) 2009-07-21 US disclosed
US-7563900-B2 Process for the preparation N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methane sulfonamido-dibenzo[b,d]furan-1-carboxamide GLENMARK PHARMACEUTICALS S.A. (CH) 2009-07-21 US disclosed
US-7563900-B2 Process for the preparation N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methane sulfonamido-dibenzo[b,d]furan-1-carboxamide GLENMARK PHARMACEUTICALS S.A. (CH) 2009-07-21 US disclosed
EP-1799632-A2 PROCESS FOR THE PREPARATION OF N-(3,5-DICHLOROPYRID-4-YL)-4-DIFLUOROMETHOXY-8-METHANESULFONAMIDO-DIBENZO[B,D]FURAN-1-CARBOXAMIDE Glenmark Pharmaceuticals S.A. (CH) 2007-06-27 EP disclosed
US-20060135779-A1 Process for the preparation n-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methane sulfonamido-dibenzo[b,d]furan-1-carboxamide GLENMARK PHARMACEUTICALS S.A. (CH) 2006-06-22 US disclosed
WO-2006040652-A2 PROCESS FOR THE PREPARATION OF N-(3,5-DICHLOROPYRID-4-YL)-4DIFLUOROMETHOXY-8-METHANESULFONAMIDO-DIBENZO[B,D]FURAN-1-CARBOXAMIDE GLENMARK PHARMACEUTICALS S.A. (US) 2006-04-20 WO disclosed
WO-2006040652-A2 PROCESS FOR THE PREPARATION OF N-(3,5-DICHLOROPYRID-4-YL)-4DIFLUOROMETHOXY-8-METHANESULFONAMIDO-DIBENZO[B,D]FURAN-1-CARBOXAMIDE GLENMARK PHARMACEUTICALS S.A. (US) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135779-A1 Process for the preparation n-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methane sulfonamido-dibenzo[b,d]furan-1-carboxamide HCN4, REN, QDPR TTR 2396/4885CYP19A1 3307/4885MAPT 3991/4885
US-20090281146-A1 PROCESS FOR THE PREPARATION OF N-(3,5-DICHLOROPYRID-4-YL)-4-DIFLUOROMETHOXY-8-METHANESULFONAMIDO-DIBENZO[B,D]FURAN-1-CARBOXAMIDE DHODH, QDPR, DPYD TTR 3224/4885CYP19A1 3443/4885MAPT 4121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.